Goutham Sunny: TILs may serve as valuable Prognostic Biomarkers in HER2+ mBC
Goutham Sunny, Resident Doctor at The Gujarat Cancer and Research Institute, shared an article on X:
“A multicenter Italian study of 110 patients with HER2+ metastatic breast cancer (mBC) treated with pertuzumab, trastuzumab & taxane chemo found that high tumor-infiltrating lymphocytes (TILs >5%) were linked to longer progression-free and overall survival.
TILs were higher in primary tumors vs metastases (p=0.009) and varied by metastatic site. These findings suggest TILs may serve as valuable prognostic biomarkers in HER2+ mBC, warranting further prospective validation.”
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment.
Authors: Beatrice Taurelli Salimbeni, Fabiola Giudici, Carlo Pescia, Pier Paolo Maria Berton Giachetti, Roberta Scafetta, Paola Zagami, Antonio Marra, Dario Trapani, Angela Esposito, Simone Scagnoli, Bruna Cerbelli, Andrea Botticelli, Elisabetta Munzone, Nicola Fusco, Carmen Criscitiello, Giuseppe Curigliano.
You can read the Full Article on Journal of NPJ Breast Cancer.
Read more about Metastatic Breast Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023